News | Radiopharmaceuticals and Tracers | May 13, 2016

NorthStar Medical Radioisotopes Expanding University of Missouri Research Reactor Operations

Von Gahlen International to design and install new high-capacity filling line to quadruple molybdenum-99 dispensing capacity

May 13, 2016 — NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Mo., adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99).

NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include a high-capacity DPharm unit to fill source vessels quickly, along with companion nuclear radiation containment chambers, or “hot cells.” Installation is scheduled to begin in November, with full operability targeted for the first half of 2017.

With the expansion, NorthStar is investing more than $3 million in its development of new processes for producing Mo-99 without the use of highly enriched uranium (HEU) and becoming the first producer of Mo-99 in the United States in more than 25 years.

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. It is used in approximately 40,000 procedures worldwide daily to diagnose and stage cancer, heart disease, infection, inflammation and other conditions.

Currently, all Mo-99 is produced overseas and most is produced in aging reactors using weapons-usable HEU, creating safety and national security concerns and the risk of product shortages. NorthStar is developing two non-uranium-based production processes that would help establish a domestic supply of Mo-99 and resolve the issues related to nuclear proliferation and the disposal of highly toxic radioactive waste.

In addition to significantly increasing dispensing capacity at MURR, the new filling line will be able to prepare source vessels containing Mo-99 generated from natural or enriched molybdenum-98 (Mo-98) targets. Enriched targets have higher concentrations of Mo-98 and produce approximately three times more Mo-99 than natural targets – 18-19 curies (Ci) compared to 6 Ci. A curie is a unit of radioactivity.

MURR will use the neutron capture production process being developed by NorthStar to supply Mo-99 through its Drug Master File. A Mo-98 target is bathed in neutrons, transforming a portion of it into Mo-99. The Mo-99 is extracted from the target and purified, and then moved to the NorthStar dispensing operation housed in the same facility. Waste created during Mo-99 production is minimal and relatively benign, making its disposal safe and inexpensive.

Source vessels are then filled with a Mo-99 solution using the DPharm and then shipped to customers for use with the RadioGenix isotope separation system. The RadioGenix system is used to extract the Tc-99m from the Mo-99, giving the radiopharmacy the key ingredient needed to create patient-ready doses of medical isotopes.

For more information: www.northstarnm.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...